share_log

SVB Leerink Initiates Coverage On Trevi Therapeutics With Outperform Rating, Announces Price Target of $6

Benzinga Real-time News ·  Nov 22, 2022 19:15

SVB Leerink analyst Thomas Smith initiates coverage on Trevi Therapeutics (NASDAQ:TRVI) with a Outperform rating and announces Price Target of $6.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment